Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXP107-11 + Gemcitabine in Advanced Pancreatic Cancer
NCT01182246Phase 2Unknown
- Sponsor
- Axcentua Pharmaceuticals AB
- Start
- Nov 2010
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axp107-11 in pancreatic adenocarcinoma (PDAC), sponsored by Axcentua Pharmaceuticals AB. Primary endpoints: Safety Profile up to 6 months, Maximum Tolerated Dose up to 6 months and 1 more. Status: unknown.
02
Drugs
axp107-11
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01182246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01182246.